secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001759425-25-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum reports 2024 net product sales $336.4M; guides 2025 sales $420M-$435M
---------------------------------------------------------------------------

- 2024 net product sales $336.4M, up from $178.9M in 2023; LIVMARLI sales $213.3M, Bile Acid Medicines $123.1M.
- 2025 global net product sales guidance of $420M to $435M; expects positive cash flow.
- Volixibat VISTAS PSC study expected to complete enrollment H2 2025; topline data in 2026.
- Cash, equivalents and investments $292.8M as of Dec 31, 2024 (vs $286.3M end 2023).
- CTEXLI (chenodiol) approved in US for cerebrotendinous xanthomatosis; MRM-3379 Phase 2 in FXS expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000012/0001759425-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000012/mirm-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001759425-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer